It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Spreading depression (SD) is an intense and prolonged depolarization in the central nervous systems from insect to man. It is implicated in neurological disorders such as migraine and brain injury. Here, using an in vivo mouse model of focal neocortical seizures, we show that SD may be a fundamental defense against seizures. Seizures induced by topical 4-aminopyridine, penicillin or bicuculline, or systemic kainic acid, culminated in SDs at a variable rate. Greater seizure power and area of recruitment predicted SD. Once triggered, SD immediately suppressed the seizure. Optogenetic or KCl-induced SDs had similar antiseizure effect sustained for more than 30 min. Conversely, pharmacologically inhibiting SD occurrence during a focal seizure facilitated seizure generalization. Altogether, our data indicate that seizures trigger SD, which then terminates the seizure and prevents its generalization.
Spreading depression is a prolonged depolarization in the CNS associated with several neurological diseases. Here the authors demonstrate a reciprocal relationship between spreading depression and seizures in an animal model.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details







1 Massachusetts General Hospital, Harvard Medical School, Neurovascular Research Unit, Department of Radiology, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); Charité–Universitätsmedizin Berlin, Klinik und Hochschulambulanz für Neurologie und Centrum für Schlaganfallforschung Berlin (CSB), Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662)
2 Massachusetts General Hospital, Harvard Medical School, Neurovascular Research Unit, Department of Radiology, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, USA (GRID:grid.32224.35)
3 Massachusetts General Hospital, Harvard Medical School, Neurovascular Research Unit, Department of Radiology, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924)
4 Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, USA (GRID:grid.32224.35)
5 Charité–Universitätsmedizin Berlin, Klinik und Hochschulambulanz für Neurologie und Centrum für Schlaganfallforschung Berlin (CSB), Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662)
6 The Pennsylvania State University, Center for Neural Engineering, Departments of Engineering Science and Mechanics and Physics, State College, USA (GRID:grid.29857.31) (ISNI:0000 0001 2097 4281)